Abstract
Two Phase 3 placebo‐controlled trials of the anti‐amyloid monoclonal antibody gantenerumab failed to result in a slowing of clinical decline in adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. Use of gantenerumab did result in a reduction in brain amyloid plaque levels. Results of the trials were published Nov. 16, 2023, in the New England Journal of Medicine.
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have